<DOC>
	<DOCNO>NCT00720031</DOCNO>
	<brief_summary>Most HLA-A2 melanoma express Melan-A/MART-1 antigen recognize tumor reactive Melan-A specific T lymphocyte . By use blood sample HLA-A2 melanoma patient ( stage III IV ) , goal produce tumor reactive Melan-A specific T cell clone conduct phase I-II clinical trial , base infusion several million several billion lymphocytes patient , order induce passive immunity antigen . Production clone perform Unit Cellular Gene Therapy Nantes University Hospital . Therapeutic response , safety treatment also localization survival infuse T cell clone assess . This approach expect precise ability clone migrate within tumor transfer specific immunity .</brief_summary>
	<brief_title>Treatment Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>HLAA2 melanoma patient : either locoregional lymph node metastasis transit nodule surgically resectable measurable cutaneous visceral metastasis Patients ' tumor express MelanA/MART1 antigen . No chemotherapy treatment ( except Deticene use first T cell clone infusion ) radiotherapy immunotherapy last 4 week infusion . No melanoma treatment protocol . Life expectancy great 6 month . General state Karnowsky great 80 , ECOG = 0 , 1 2 . Patient negative HIV B C hepatitis . Biological parameter begin study : leucocytes ³ 2000 element per mm3 , hemoglobin ³ 10.5g/dl , platelet ³ 100 000 per mm3 , phosphatases alcalines transaminase £ 1 time 1/2 compare normal . Signed informed consent Cardiovascular pathology , evoluting uncontrolled , ( severe HTA ) , cardiac deficiency , severe angor , severe arrhythmia . Infectious pathology evoluting require antibiotherapy . Patients HIV+ . Transplanted patient patient suffer severe autoimmune disease . Psychiatric trouble allow protocol followup . Pregnant breastfeed woman . No contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Melanoma ,</keyword>
	<keyword>Melan-A tumor reactive T cell clone ,</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>HLA-A2 melanoma patient</keyword>
	<keyword>either loco-regional lymphnode metastasis</keyword>
	<keyword>transit nodule surgically resectable</keyword>
	<keyword>-measurable cutaneous visceral metastasis .</keyword>
	<keyword>Patients ' tumor express Melan-A/MART-1 antigen .</keyword>
</DOC>